IFITM5 and osteogenesis imperfecta type 5: In that respect, Hanagata et al. [36] have investigated whether in vivo treatment with FK506 in a model of OI type V could inhibit Ifitm5 expression, and/or its interaction with FKBP11 that they had previously identified [25].